Related Experiment Video
Updated: Jun 13, 2025

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
Published on: December 15, 2023
Current advances in Hepatitis C diagnostics
Anna S Baber1, Baviththira Suganthan1, Ramaraja P Ramasamy2
1Nano Electrochemistry Laboratory, College of Engineering, University of Georgia, Athens, GA, 30602, USA.
Insights
Hepatitis C Virus (HCV) diagnostics face barriers. Novel methods like isothermal amplification and self-contained systems aim for faster, accessible HCV testing, especially for at-risk populations.
Area of Science:
- Hepatology
- Virology
- Medical Diagnostics
Background:
- Hepatitis C Virus (HCV) infects nearly 60 million globally, causing liver cirrhosis and hepatocellular carcinoma.
- High-burden populations (IDUs, LMICs) face diagnostic barriers due to slow, costly current methods.
- HCV lacks a vaccine, and asymptomatic infection necessitates effective screening to prevent liver damage and transmission.
Purpose of the Study:
- To review current commercial standards and novel improvements in Hepatitis C Virus diagnostics.
- To outline a framework for developing a one-step diagnostic test for HCV.
- To address the unmet needs in HCV diagnosis for high-risk and underserved populations.
Main Methods:
- Review of current commercial Hepatitis C Virus diagnostic platforms.
- Analysis of emerging diagnostic technologies including isothermal amplification and viral protein analytes.
- Evaluation of streamlined, self-contained testing systems for reduced complexity.
Main Results:
- Current HCV diagnostics are often slow and expensive, hindering timely treatment.
- Novel approaches show promise for rapid, sensitive, and accessible Hepatitis C Virus detection.
- Improvements focus on simplified workflows and reduced need for specialized laboratory infrastructure.
Conclusions:
- Advancements in HCV diagnostics are crucial for global health equity.
- Integration of novel techniques can lead to a more efficient, one-step diagnostic solution.
- Future diagnostics must prioritize accessibility and affordability for populations most affected by Hepatitis C Virus.
Abstract:
Nearly 60 million people worldwide are infected with Hepatitis C Virus (HCV), a bloodborne pathogen which leads to liver cirrhosis and increases the risk of hepatocellular carcinoma. Those with limited access to healthcare resources, such as injection drug users and people in low- and middle-income countries, carry the highest burden. The current diagnostic algorithm for HCV is slow and costly, leading to a significant barrier in diagnosis and treatment for those most at risk from HCV. There remains no available vaccine for HCV, and infection is often asymptomatic until significant cirrhosis has occurred, which makes screening incredibly important to prevent liver damage and transmission. Recent investigation has sought to address these issues through improvements in various aspects of the diagnostic procedure, using methods such as isothermal amplification techniques for viral RNA amplification, the use of viral protein as an analyte, and the incorporation of streamlined, self-contained testing systems to reduce administrative skill requirements. This review provides a comprehensive overview of current commercial standards and novel improvements in HCV diagnostics, as well as a framework for future integration of these improvements to develop a one-step diagnostic that meets the needs of those most affected.

